China's growing dominance in pharmaceuticals is not accidental but a deliberate, 30-year national strategy. It began with cornering the market for low-cost active pharmaceutical ingredients (APIs), then generics, and now is focused on becoming the global leader in innovative biotech by 2035.

Pfizer's CEO warns that China's meticulously executed national plan for pharma—improving regulators, strengthening IP, and funding science—is a disruptive force. Operating at half the cost and three times the speed, China is on track to lead in multiple areas of drug discovery within 1-2 years.

The increasing number of novel drugs from China is viewed not just as a national success, but as evidence of a broader global trend: the commodification of key drug development technologies. This makes R&D cheaper, faster, and more reproducible, allowing innovation to flourish in new regions.

Jeremy Levin outlines China's deliberate, 25-year strategic plan for biotech, moving from API production to CROs, attracting scientific talent, creating lookalikes, and now developing novel medicines. He warns that unless the U.S. treats biotech as a strategic asset, China's state-driven approach will make it the dominant innovator within five years, partly funded by Western pharma investments.

Contrary to the goal of onshoring critical industries, the U.S. is increasingly relying on Chinese biotech for new medicines. Drug in-licensing from China is projected to skyrocket from $5 billion in 2020 to an expected $60-70 billion by 2025, signaling a major shift in global pharmaceutical power.

China rapidly overtook established players by executing a national strategy for pharma innovation. They built a comprehensive ecosystem that includes attracting top overseas talent with incentives, providing state-backed venture capital, massively funding university research, and creating a large home market for innovative drugs.

The most significant shift isn't just Asia's rising share of the global drug pipeline (43%), but its contribution to its growth. A staggering 85% of the net new growth in innovative drug pipelines in 2024 originated from Asia, signaling a fundamental change in the global R&D landscape.

Beyond sheer scale, China's innovation leads in complex, next-generation drug modalities like ADCs and bispecifics. Chinese biotechs now account for roughly one-third of the global Phase 1 and 2 pipelines for these advanced therapies, indicating a shift from iteration on established targets to leadership in new technology platforms.

Since 2016, China has rapidly reformed its systems, moving from a laggard to the global leader in initiating clinical trials. This lead extends beyond simple volume to pioneering completely new therapies, particularly in areas like cell and gene therapy.